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Background: Transfusion of red blood cells (RBC) is recommended in septic shock and the majority of these
patients receive RBC transfusion in the intensive care unit (ICU). However, benefit and harm of RBCs have not been
established in this group of high-risk patients.
Methods/Design: The Transfusion Requirements in Septic Shock (TRISS) trial is a multicenter trial with
assessor-blinded outcome assessment, randomising 1,000 patients with septic shock in 30 Scandinavian ICUs to
receive transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM)
at haemoglobin level (Hb) of 7 g/dl or 9 g/dl, stratified by the presence of haematological malignancy and centre.
The primary outcome measure is 90-day mortality. Secondary outcome measures are organ failure, ischaemic
events, severe adverse reactions (SARs: anaphylactic reaction, acute haemolytic reaction and transfusion-related
circulatory overload, and acute lung injury) and mortality at 28 days, 6 months and 1 year.
The sample size will enable us to detect a 9% absolute difference in 90-day mortality assuming a 45% event rate
with a type 1 error rate of 5% and power of 80%. An interim analysis will be performed after 500 patients, and the
Data Monitoring and Safety Committee will recommend the trial be stopped if a group difference in 90-day
mortality with P ≤0.001 is present at this point.
Discussion: The TRISS trial may bridge the gap between clinical practice and the lack of efficacy and safety data on
RBC transfusion in septic shock patients. The effect of restrictive versus liberal RBC transfusion strategy on mortality,
organ failure, ischaemic events and SARs will be evaluated.
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Trial registration: ClinicalTrials.gov: NCT01485315. Registration date 30 November 2011. First patient was
randomised 3 December 2011.
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The first line treatments for patients with septic shock are
antibiotics, source control and resuscitation with intrave-
nous fluids and vasopressor/inotropic drugs to optimise
circulation and organ perfusion. These interventions may
be supplemented with red blood cells (RBCs) in case of
anaemia and persistent hypoperfusion [1].
It is known from large prospective studies in European
and North American intensive care units (ICUs) that an-
aemia is very common in critically ill patients; 65% of
critically ill patients have haemoglobin (Hb) level <12 g/dl
(7.4 mM) at time of admission to the ICU and a mean
admission Hb level of 11.3 g/dl (7 mM) [2,3]. As a result
of this, 40 to 50% of patients admitted to ICUs are trans-
fused with RBCs during their stay, and 90% of transfu-
sions are administered to non-bleeding patients with a
mean of 5 units of RBC per transfused patient. The mean
pre-transfusion Hb level - the trigger - in ICU patients is
reported to be around 8.5 g/dl (5.3 mM) [4,5].
RBC transfusion has traditionally been perceived as an
effective treatment for patients with anaemia - especially
for patients with clinical signs of reduced tissue oxygen-
ation [6]. The main function of RBCs is to transport oxy-
gen from the pulmonary to the peripheral capillaries. Thus,
RBCs are administered to increase Hb levels and thus
blood oxygen-carrying capacity in patients with sepsis to
prevent tissue hypoxia and thereby multiple organ failure.
However in patients with septic shock, oxygen delivery
(DO2) may increase after RBC transfusion without a corre-
sponding increase in oxygen consumption (VO2) [7]. Sev-
eral mechanisms may lie behind this observation.
Firstly, tissue hypoxia in the early phase of sepsis might
be due to heterogeneous perfusion (stagnant hypoxia) [8],
which may not be amenable to RBC transfusion. Secondly,
the stored RBCs may not deliver oxygen as efficient as
native cells, perhaps due to biochemical and rheological
changes of the RBC suspension ex vivo, so called storage
lesion [9,10]. Thirdly, organ cells may be unable to exploit
the increase in oxygen tension due to mitochondrial
changes and such cytopathic hypoxia [11] will not be
amenable to increased DO2 in general [12,13].
In addition, RBC suspensions may have immunomod-
ulatory properties, which can be harmful to patients with
sepsis [14,15].
The two trials randomising adult patients with sepsis
to different RBC transfusion strategies have shown diver-
gent results. The trial by Rivers and colleagues indicatedincreased survival with a complex early goal-directed pro-
tocol (the goal being central venous oxygen saturation
(ScvO2) ≥70%) including RBC transfusion. Mortality was
31% with early goal-directed therapy versus 47% in controls,
but the role of RBC transfusion was unclear since transfu-
sion was given only if hypoperfusion persisted after initi-
ation of mechanical ventilation, fluid and administration of
inotropic drugs [16]. On the other hand, the Transfusion
Requirements in Critical Care (TRICC) trial randomising
838 resuscitated and normovolaemic ICU patients to a
transfusion trigger of either 7 g/dl (4.3 mM) (restrictive) or
10 g/dl (6.2 mM) (liberal) found no significant difference in
the primary outcome measure - 30-day mortality - between
the two groups [17]. Hospital mortality was higher in the
liberally transfused patients, who also had significantly more
cardiopulmonary complications in the ICU than those in
the restrictive group. Predefined subgroup analyses indi-
cated lower mortality in the restrictive transfusion group in
younger (age <55 years) and less severely ill patients (Acute
Physiology and Chronic Health Evaluation (APACHE) II-
score <20).
The results of this trial should be interpreted with cau-
tion, since the planned inclusion of 1,600 patients was
not achieved due to slow recruitment. The patient popu-
lation may not be representative for ICU patients in gen-
eral because cardiovascular disease was more common
in the excluded patients than in the included. Thus, po-
tential negative effects of restrictive transfusion practice
in cardiac patients may not have been discovered. Fur-
thermore the patients were transfused with non-leuko-
depleted RBCs stored in citrate suspension, making it
difficult to adapt the results to clinical practice today, where
pre-storage leuko-depleted blood is widely used. Finally, all
patients were resuscitated and deemed normovolaemic by
the clinicians when randomised and therefore less likely to
have tissue hypoperfusion.
A cochrane review published in 2012 [18] found 19
randomised clinical trials, involving 6264 patients, examin-
ing the effects of transfusion thresholds on different out-
come variables. Three trials included intensive care patients
and one of these was in paediatric patients. Most of the
mortality data (52%) came from the TRICC trial [17]. In
this review, restrictive transfusion strategy did not increase
the rate of adverse events (that is, mortality, cardiac events,
myocardial ischaemia, stroke, pneumonia and thrombo-
embolism) compared to liberal transfusion strategies. Fur-
thermore restrictive transfusion strategies were associated
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Figure 1 Transfusion trigger levels in Denmark. The figure shows
the lowest haemoglobin level measured 0 to 2 hours before red
blood cell (RBC) transfusion in 213 consecutive septic shock patients
in 7 Danish ICUs. The data represent 358 transfused units of
saline-adenine-glucose-mannitol (SAGM) [20]. To convert values in
mM to g/l multiply with 1.6.
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hospital mortality but not 30-day mortality. The authors of
the Cochrane review concluded that current evidence sup-
ports the use of a restrictive transfusions strategy for most
patients, including patients with pre-existing cardiovascular
disease, but more research is needed to evaluate the effects
of restrictive transfusion in high-risk patients.
Taken together, RBC transfusion for patients with sep-
tic shock remains controversial because important effi-
cacy and safety questions have not been firmly addressed
in previous trials. The optimal Hb-guided transfusion
strategy that outbalances risk and benefit remains to be
established in this subgroup of high-risk patients.
Aim
The aim of the TRISS trial is to assess the effects of two
well-defined Hb-trigger guided transfusion strategies on
mortality and morbidity in ICU patients with septic shock.
Methods/Design
This is a multicentre trial with computer generated al-
location sequence, centralised stratified randomisation,
concealed allocation, and blinded outcome assessment
of patients with septic shock. The patients will be stratified
by centre and by the presence or absence of haemato-
logical malignancy and randomised 1:1 to RBC transfusion
at Hb ≤7 g/dl (4.3 mM) or Hb ≤9 g/dl (5.6 mM). The
latter stratification variable was chosen because these pa-
tients have very high mortality rates (70% at 90 days in the
6S trial [19]) and will only be included at few trial sites.
Therefore, centre stratification alone may not ensure equal
distribution of these patients into the two trial arms.
Hypothesis
The present evidence is not sufficient to support either
restrictive or liberal transfusion strategy in ICU patients
with septic shock underlining the need for this trial. The
transfusion triggers chosen for this trial are well within
the range of the current transfusion practice. We do not
have a priori expectations on superiority/inferiority of
one of the transfusion strategies in this trial. However, a
restrictive transfusion strategy in patients with septic
shock has the potential to reduce the relative risk of
death by 20% (9% absolute risk reduction) compared
with a liberal strategy based on the subgroup of patients
with severe infection in the TRICC trial [17].
Trial interventions
Enrolled patients are given a RBC transfusion when they
reach their assigned trigger level (Hb ≤9 g/dl (5.6 mM) or
7 g/dl (4.3 mM)) during the entire ICU stay to a max-
imum of 90 days after randomisation. After ICU discharge
or 90 days after randomisation transfusions are given at
the discretion of the clinicians despite group allocation. Ifthe patient is readmitted to the ICU within 90 days after
randomisation, the Hb-trigger value assigned at random-
isation will be reused regardless of the readmission diag-
nose or status.
RBCs will be transfused as single units followed by
renewed Hb assessment by point-of-care testing within
3 hours of termination of the last transfused unit or be-
fore the initiation of a new transfusion. All other inter-
ventions will be at the discretion of clinicians.
The choice of the two transfusion triggers is based on
data from observational studies representing current trans-
fusion practice in septic shock patients in Scandinavia
[5,20] [Figure 1].
All trial sites will use pre-storage leuko-depleted RBCs
suspended in saline-adenine-glucose-mannitol (SAGM).
The intervention is to be administered as an intravenous
infusion after making sure that a match of recipient and
donor blood has been carried out. The exact amount of
blood (ml) in each unit and the exact amount of blood
transfused will be recorded by the clinical staff on a
transfusion registration sheet when SAGM transfusions
are initiated and terminated.
Concomitant medication/treatment
All other interventions will be at the discretion of
the clinicians.
Inclusion criteria
Adult (age 18 years or above) patients in the ICU who:
 Have anaemia (Hb ≤9 g/dl (5.6 mM))
AND
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Additional file 1] [21]:
a) Fulfil at least two systemic inflammatory response
syndrome (SIRS) criteria within the last 24
hours [22]
And
b) Has a suspected or verified focus of infection
And
c) Has hypotension (systolic or mean arterial blood
pressure ≤90 mmHg or ≤70 mmHg, respectively)
despite fluid therapy OR requires infusion of
vasopressor/inotropic agents to maintain blood
pressure.Exclusion criteria
Patients fulfilling one or more of the following criteria
will not be included:
 Documented wish against transfusion
 Previous SAR with blood products (except
transfusion-associated circulatory overload (TACO))
 Presence of ongoing myocardial ischaemia at time of
randomisation ((defined as: 1) Patients diagnosed
with : a) acute myocardial infarction (ST-elevation
myocardial infarction or non-ST elevation
myocardial infarction) or b) unstable angina pectoris
during current hospital admission, according to the
criteria in the clinical setting in question (for
example, elevated biomarkers, ischaemic signs on
ECG, clinical presence) AND 2) the patient has
received treatment, initiated during current hospital
admission, as a consequence of this (reperfusion
strategies (PCI/thrombolysis) or initiated/increased
antithrombotic drug treatment))
 Life-threatening bleeding at time of randomisation
defined as: (1) Presence of haemorrhagic shock, as
judged by research or clinical staff OR (2) the need
for surgical procedure, including endoscopy to
maintain Hb levels
 RBC transfusion during current ICU admission,
administered before randomisation
 Withdrawal from active therapy or brain death
 Acute burn injuries regardless of severity or total
burn surface area
 Lack of informed consent (in Sweden, Norway,
Finland and Iceland consent is obtained from next
of kin prior to randomisation; in Denmark delayed
consent is obtained from next of kin and general
practitioner after randomisation), [Figure 2].
Randomisation
Screening and randomisation are centralised, web-based,
and accessible 24-hour around-the-clock according to
the allocation list, the stratification variables and varyingblock size created by the Copenhagen Trial Unit (CTU)
and kept secret from the investigators to allow immedi-
ate and concealed allocation to the intervention.
Primary outcome measure
 Mortality 90 days post-randomisation
Secondary outcome measures
 Mortality within the whole observation period
reported at day 28, 6 months and 1 year after
randomisation of the last patient
 Life support at day 5, 14 and 28 post randomisation
as use of mechanical ventilation, renal replacement
or vasopressor/inotropic therapy [23]
 Severe adverse reactions in the ICU including
anaphylactic/allergic reactions, acute haemolysis,
transfusion-associated acute lung injury (TRALI),
and transfusion associated circulatory overload
(TACO)
 Ischaemic events in the ICU including acute
myocardial-, cerebral-, intestinal- and acute
peripheral limb ischaemia
 Days alive and out of hospital
 Days alive without mechanical ventilation in the
90 days after randomisation
 Days alive without dialysis/haemofiltration in the
90 days after randomisation
 Days alive without vasopressor/inotropic therapy
in the 90 days after randomisation
 Health-related quality of life (HRQoL) for Danish
patients assessed using the Physical and Mental
Component Summary (PCS and MCS) scores of
the country specific Short Form health survey
questionnaire (SF-36 [24,25]) one-year after
randomisationBlinding
It will not be feasible to mask the assigned transfusion
strategy from health care providers. Consequently, clin-
ical staff caring for the patients will be aware of the allo-
cation and correlated intervention bias as well as other
bias mechanisms that may not be controlled. However,
information on whether the primary outcome of death
occurred will be acquired through the National Civil
Registries immediately before the interim analysis and the
final data analyses. Thus, steering committee members or
investigators will have no knowledge to enable them to
compare outcome variables with intervention group allo-
cation for any patient. The independent trial statistician
will also be blinded for the allocation during analysis. In-
formation on the secondary outcomes, except long-term
mortality, will be provided by the local investigators from
YES
NO
Discharge from ICU
Assessed for eligibility 
Excluded when: 
Wish against transfusion OR
Previous SAR with blood 
products OR
Acute coronary syndrome OR
Presence of life threatening 
bleeding OR
RBC transfusion during current 
ICU admission OR
Withdrawal from active therapy or 
brain death
Acute burn injuries regardless of 
severity or total burn surface area
Lack of informed consent 
(depending on national law)
Primary outcome : 
Mortality at day 90 
Secondary outcome : 
Mortality at 28-day and 6 months and 12 months
Life support at day 5, 14 and 28 post-randomisation
Severe adverse reactions
Ischaemic events in the ICU
Length of stay in ICU and hospital
Days in need of life support among survivors
Health-related quality of life 
Transfused when Hb < 7.0 g/dl (4.3 mM)
Pt transfused with 1 RBC unit at a time 
followed by new Hb point of care testing 
within 3 hours or before another transfusion 
is initiated.
Follow-Up
Enrolment
Randomisation
Transfused when Hb < 9.0 g/dl (5.6 mM)
Pt transfused with 1 RBC unit at a time 
followed by new Hb point of care testing 
within 3 hours or before another 
transfusion is initiated.
Allocation:
Until discharge 
from ICU, death or 
day 90 from 
randomisation
Included when: 
Patient in the ICU AND
Age > 18 years AND
Fulfil the criteria for septic 
shock AND
Have Hb < 9 g/dl (5.6 mM) 
AND
Consent obtainable from 
patient or proxy
Figure 2 Transfusion requirements in septic shock (TRISS) trial flow diagram.
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will be blinded for the allocation. The members of the data
and safety monitoring committee (DMSC) will remain
blinded unless they request otherwise and after the in-
terim analysis has provided strong indications of one
intervention being beneficial or harmful.
Participant withdrawal
Patients may be withdrawn from the trial at any time if
consent is withdrawn by the person(s), who has given
proxy consent or by the patient.
The person(s) demanding withdrawal from trial inter-
vention will be asked for permission to continue dataregistration. In the event the patient does not prohibit
obtaining information on the primary outcome measure,
it will be obtained centrally. Thus, there may be the fol-
lowing types of withdrawal:
 From intervention only (allowing for all data
registration and follow-up)
 From intervention and further registration (but
maintaining already registered data and centralised
outcome assessment)
 From intervention, further registration, follow-up,
and previously registered data demanding deletion
of already registered data. Only the patient can
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if the patient did not consent previously.
If patients deny use of data, we are obliged to delete
all data. We expect few of these denials and that the trial
will continue until full sample size has been reached to
maintain statistical power without further violating the
randomisation scheme [19].
Patients who are transferred to another ICU will be
withdrawn from the transfusion protocol. However, if
the new ICU is an active trial site, the allocated transfu-
sion Hb-trigger level will be maintained in this new ICU.
In any case, patients who are transferred to another ICU
will be followed up for the primary outcome measure.Suspension of protocol
The protocol may temporarily be suspended for the indi-
vidual patient, at the discretion of the attending doctor,
in case of [see Additional file 2 for details]:
 Life-threatening bleeding or
 Ischaemic events
After stabilisation in these instances, the patient will
re-enter the protocol. For non-life-threatening bleed-
ing, including surgical procedures, the protocol will be
maintained.Severe adverse reactions
Serious Adverse Reactions will be registered and are [see
Additional file 3 for details]:
 Anaphylactic/allergic reactions
 Severe haemolytic complications
 Transfusion associated acute lung injury (TRALI)
 Transfusion associated circulatory overload (TACO)
Patients who experience a SAR will not be withdrawn
from the trial protocol.Use of hydroxyethyl starch
The recently completed Scandinavian Starch for Severe
Sepsis/Septic Shock (6S) trial showed significantly increased
mortality (51% versus 43%, P = 0.03) and use of renal re-
placement therapy (RRT) (22% versus 16%, P = 0.04) in pa-
tients with severe sepsis or septic shock who received HES
130/0.42 compared with those receiving Ringer’s acetate
[18]. These findings are supported by other recent trials
[26,27]. Therefore, we prohibit the use of all starch prepara-
tions (that is, Voluven™, Tetraspan™ etcetera) in the TRISS
trial.Statistics
For this study, 2 × 500 patients will be needed to show a
9% absolute risk difference in 90-day mortality (relative
risk reduction of 20% with restrictive transfusion among
patients with severe infection in the TRICC trial) and
mortality of 45% (obtained from 41% in the East Danish
Septic Shock Cohort [28] and 51% in a later cohort of
septic shock patients in Danish ICUs [29], alpha of 0.05
(two-sided) and power of 80% (1-beta). The Trial Se-
quential Analysis [30] showed that at least an informa-
tion gap of 1,000 patients may be expected assuming a
19% relative risk reduction of mortality, and a diversity
(D-square) of 0%, and a control event percentage of 11%
as found in the traditional meta-analysis of the relevant
trials. A type 1 and 2 error rate of 5% and 10%, respec-
tively, were used for the trial sequential analysis [see
Additional file 4].
The primary analyses will be by intention-to-treat
comparing the two groups by logistic regression analysis
for binary outcome measures adjusted for stratification
variables (site and presence of haematological disease).
An unadjusted Chi-square test for differences in the bi-
nary outcomes will be done as a co-primary analysis.
We will perform per protocol analyses of the primary
outcome and the most important secondary outcomes
excluding patients with one or more major protocol
violations [see Additional file 5]. SAS software, version
9.3 (Cary, NC, US) will be used for data management
and analysis.
Interim analysis
An interim analysis will be conducted when patient num-
ber 500 has been followed for 90 days [see Additional file 6
for details].
The independent DMSC will recommend pausing or
stopping the trial if it finds:
 A group difference in the primary outcome measure
P <0.001 (Haybittle-Peto criterion) [31,32]. If an
analysis of the interim data from 500 patients fulfils
the Haybittle-Peto criterion the inclusion of further
patients will be paused and an analysis including
patients randomised during the analysis period will
be performed. If this second analysis also fulfils the
Haybittle-Peto criterion or if the group sequential
monitoring boundaries are reached the DMSC will
recommend stopping the trial.
 Results from other trials combined with the interim
analysis from the TRISS trial show clear benefit or
harm with RBC transfusion in meta-analysis using trial
sequential analysis [30] with a diversity-adjusted
required information size [33] based on an a priori
relative risk reduction of 10%, an overall type 1 error
rate of 5% and a type 2 error rate of 20% (power of
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of 45%.
Intervention accountability
Every patient will be allocated a transfusion registration
sheet. This will be kept on site in the site master file.
The transfusion registration sheet will include the allo-
cated patient screening number, time for initiation of
transfusion and unit volume.
Registration
Data will be registered into the electronic web-based
case report form (eCRF) from patient notes (source data)
by trial site personnel. The CTU in cooperation with the
coordinating investigator will establish the trial database
from an export of data from the eCRF. Paper CRF will
be used in case of technical difficulties. Any deviation
from the protocol will be captured either in the eCRF or
in notes-to-file. Data registration is performed at each
participating site by trained personnel.
The following data will be registered
Pre-randomisation and baseline characteristics: Basic pa-
tient characteristics (national identification number or date
of birth and site of inclusion (dependent on national law),
sex, estimated weight, suspected or confirmed site of infec-
tion, surgery during current admission (emergency, elective
or not), date of admission to hospital and date and time of
admission to ICU and from where the patient was admit-
ted to ICU, co-morbidity (haematological malignancy or
not (assessed at screening), chronic obstructive pulmonary
disease, asthma or other chronic lung disease or not, car-
diovascular disease or not (defined by history of acute
myocardial infarction, stable/unstable angina pectoris, pre-
vious coronary intervention (CABG or PCI), chronic heart
failure (NYHA class 3 to 4) [34], vascular disease (as previ-
ous central (aortic or iliac) or peripheral vascular inter-
vention) or ischaemic stroke (including infarction and
transitory cerebral ischaemia) and use of RRT.
24 hours prior to randomisation: Lowest/highest Hb
level, volume of transfused blood components (specified
as RBCs, plasma and platelets), lowest values of ScvO2,
highest value of p-lactate and data for Simplified Acute
Physiology Score (SAPS) 2 [35] and Sepsis-related Organ
Failure Assessment (SOFA) scoring [36].
Daily during the entire ICU stay: Hb-levels (daily mini-
mum, maximum and number of assessments), volumes
of transfused blood products (RBCs, plasma and plate-
lets), time for initiation of RBC transfusion, unit ID,
blood storage time, fluid in-/output, renal replacement
therapy or not, vasopressor/inotropic infusion or not,
mechanical ventilation or not, lowest PaO2/FiO2, lowest
ScvO2, highest p-lactate, surgery or not, any bleeding,ischaemic events, severe adverse reactions (SAR), and
decision on not resuscitate in case of cardiac arrest.
90 days after randomisation: Survival status and hos-
pital discharge status obtained from hospital or civil
registries, and date of death if the patient has deceased.
Last day of any of the following interventions if the pa-
tient was discharged from the trial ICU receiving any of
these: Renal replacement therapy, vasopressor/inotropic
infusion and mechanical ventilation. We plan to perform
a landmark mortality analysis for all randomised patients
with a follow-up for each patients of 90 days, the pri-
mary analysis will be a logistic regression analysis ad-
justed for stratification variables. Further, we plan to
perform survival analyses including Kaplan-Meier esti-
mates within the total observation time. That is until the
last randomised patient has been followed for 3 month.
Within the total observation time we will also perform
an adjusted proportional hazards analysis (Cox regres-
sion analysis), provided the criterion on proportional
hazards is fulfilled, adjusting for all the pre-specified co-
variates listed in the protocol [37-39].
Twelve months after randomisation: Survival status
obtained from hospital or civil registries and date of death
if the patient is deceased. Days in need of life support
(mechanical ventilation, renal replacement or vasopressor/
inotropic therapy) in survivors: Status obtained from hos-
pital or civil registries. Health-related quality of life in sur-
vivors obtained by posting of the SF-36 questionnaire
followed by phone contact if the patient does not reply.
Data handling and record keeping
Data will be handled according to the data protection
agencies of the different countries. All original records
(including consent forms, eCRFs, and relevant corre-
spondences) will be archived at trial sites or at CTU for
15 years. The clean electronic trial database file will be
anonymised and delivered to the Danish Data Archive
and maintained for 15 years.
Monitoring
Monitoring will adhere to good clinical practice (GCP
[40]) principles and be performed according to a prede-
fined monitoring plan including the following issues:
 Initiation visits at all sites
 For all patients: Documented informed consent
 For all patients: Primary outcome according to
national or hospital registries
 For 100 patients being the first two patients at each
trial site, and another two patients randomly chosen
at each trial site: Documented delivery or
non-delivery in the eCRF of the intervention
according to the protocol compared with source
data being patients’ hospital records
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that all eCRFs are fulfilled according to the protocol
 Termination visit at all sites: Documenting informed
consent for all participants.
A centralised day-to-day monitoring of the eCRF and
adherence to the protocol (for example, the ability of in-
dividual centres to transfuse at assigned transfusion
values only) will be done by the coordinating investiga-
tor or his delegates. Additional monitoring visit will be
made to selected sites if the steering committee finds
this necessary based on monitoring findings.
Ethical considerations
The trial will be conducted in adherence to the current
version of the Helsinki Declaration [41] and to the stan-
dards of GCP. Screening of patients will only start after
approval by the ethics committee and data protection
agency in the countries of the trial sites.
There is no conclusive evidence from RCTs on the po-
tential benefit or risk of RBC transfusion in adults with
septic shock. RBC transfusion is part of the current
treatment of septic shock, and the Hb-trigger values
chosen for the present trial are well within those ob-
served in clinical practice. Thus, the participants will not
be exposed to known risks when included into the trial.
Furthermore, the research question is in the public’s
interest and the trial design will provide meaningful data
with the potential to reach statistical significance and
therefore lead to the acceptance or rejection of the null
hypothesis.
Ethical approvals
By 8 January 2013 the study had been approved by:
(Denmark) De Videnskabetiske Komiteer - Region
Hovedstaden (H-3-2011-114); (Sweden) Regionala
etikprövningsnämnden i Stockholm (2011/2:8) (2012/814-Figure 3 Trial status. Print from the ransfusion equirements n eptic hock (TR32); (Norway) Regionale Komiteer For Medicinsk og
Helsefaglig Forskningsetikk (2011/2270/REK vest); (Finland)
Tampereen Yliopistollisen Sairaalan Erityisvastuualueen
Alueellinen Eettinen Toimikunta (R12269).Informed consent
The majority of patients assessed for enrolment in the
trial will be unable to give informed consent because of
severe illness or as a consequence of the treatment (sed-
ation). Some patients will thus be randomised and en-
rolled before obtaining informed consent if applicable by
national law and after approval by the Ethics Committee
for each of the participating ICUs.
There is no alternative to this approach as no clinically
relevant model of septic shock exists and no conscious
patients have the combination of severe infection, shock
and multiple organ failure.
Furthermore, septic shock is an acute life-threatening
condition and rapidly initiated resuscitation according to
guidelines [1] is important to give the patient the best
chance of survival. It would therefore be unacceptable to
delay initiation of treatment while awaiting informed
consent.
As soon as possible after enrolment proxy consent will
be obtained from the patient’s next of kin or general
practitioner/regional medical officer of health according
to national law. Patients who regain consciousness, will
be asked for informed consent as soon as possible.Duration
Patients from 31 Scandinavian ICUs are expected to
be included during a 2-year inclusion period starting
December 2011. Based on data from 6S trial it is realistic
to include a mean of two patients per ICU per month [19]
[Figure 3].ISS) electronic Case Record Form showing the trial status on 19 April 2013.
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In case of low recruitment we will involve new trial sites
to reach the goal of including 1,000 patients within the
2-year time period.
Co-enrolment
We will assess the eligibility of patients included in the
TRANSFUSE trial (ClinicalTrials.gov identifier: NCT01
638416) but not of patients included in the ARISE trial
(ClinicalTrials.gov identifier: NCT00975793).
Timeline
 2011: Protocol, approvals from ethical committees, trial
tool development (eCRF and randomisation system)
 2012 to 2013: Inclusion of patients
 Mid-2013: Interim analyses
 2014: The database is expected to be closed in
March 90 days after the inclusion of the last patient.
Data analyses and writing of the manuscript will be
in April followed by submission for publication
shortly thereafter
Trial organisation
This trial is investigator-initiated as a collaborative re-
search programme between the Scandinavian Critical
Care Trials Group, Rigshospitalet, Copenhagen Trial Unit
and 31 ICUs in all the Nordic countries. [Figure 4]
Publication plan
The trial is registered on www.clinicaltrials.gov. Upon
trial completion the main manuscript will be submitted
to one of the major clinical journals regardless of the re-
sult, and the results will in any case be published at the
SCCTG home page. The Steering Committee will grant
authorship in adherence to the Vancouver guidelines
[42] and number of patients enrolled by the individual
investigator. If a trial site investigator is to gain author-
ship, the site has to include 25 patients or more. If the
site includes 50 patients or more, two authorships will
be granted per trial site, 75 patients will give three au-
thorships per trial site and so on.
Finances
The TRISS trial is funded by the Danish Council for
Strategic Research (09–066938) and Copenhagen Uni-
versity Hospital, Rigshospitalet. The funding sources will
have no influence on trial design, trial conduct, data
handling, data analysis, or publication.
Perspectives
Severe sepsis affects millions of patients worldwide with
high rates of complications and mortality. Outcome dif-
ferences between therapies for sepsis will therefore havea major impact on global health and healthcare costs. As
far as the investigators are aware, no other RCTs are
assessing the effects or safety of RBC transfusion in pa-
tients with septic shock.
Discussion
Performing the TRISS trial is in line with recommenda-
tions from the 2012 updated Cochrane review [18] and
American Association of Blood Bankers [43] guidelines,
both stating the need for trials assessing the effects of
transfusion triggers in high risk populations.
The TRISS trial may bridge the gap between clinical
practice and evidence providing urgently needed data on
the efficacy and safety of RBC transfusion for patients
with septic shock. The TRISS trial investigators have fa-
cilitated a network of Scandinavian ICUs enrolling a
high number of patients with septic shock.
Trial Status
The first patient was randomised 3 December 2011. As
of 19 March 2013 31 ICUs are participating, 779 pa-
tients have been screened, and 578 patients have been
randomised. Ethical approvals in Iceland are pending,
and we are expecting 2 to 3 new trial sites to be initiated
in the following months.
Additional files
Additional file 1: Trial criteria for septic shock.
Additional file 2: Protocol suspension criteria.
Additional file 3: Severe adverse reactions (SARs).
Additional file 4: Trial sequential analysis.
Additional file 5: Statistical analysis plan.
Additional file 6: Charter for the independent Data Monitoring and
Safety Committee (DMSC) of the TRISS trial.
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